Microsoft founder, billionaire Bill Gates has announced that he is working on a new, invisible, quantum dot digital tattoo implant to track vaccine compliance—including the new COVID-19 vaccine that pharmaceutical leaders such as Inovio Pharmaceuticals expects to be available by 2021. With funding from The Bill and Melinda Gates Foundation, Inovio has stated that they hope to have 1 million vaccine doses ready by the end of 2020 for clinical trials and emergency use, if required.

The new vaccine candidate, INO-4800, is a DNA vaccine which “delivers optimized DNA into cells, where it is translated into proteins that activate an individual’s immune system to generate a robust targeted T cell and antibody response”. Using a hand-held smart device by Inovio Pharmaceuticals, called CELLECTRA, uses brief electrical pulses to open small pores in human cells to allow the optimized DNA or plasmids to enter. Once inside the cell, the plasmids begin to replicate and, according to Inovio, strengthens the body’s own natural imnune-system response.

Dr. J. Joseph Kim, president and CEO of Inovio, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2, 2020. Dr. Kim said: “Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.”

According to Precision Vaccinations, “DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.”

Human trials began today, Monday, April 6th, as up to 40 test patients are injected in the U.S. with the new, developing trials of the COVID-19 vaccine. According to scientists, studies have been “promising” in pre-clinical animal trials. The results of the human clinical trials will be published by the Fall of this year.

The question is: will the vaccine be compulsory?